17/18 January 2007 Wiener Neustadt - Czelo
17/18 January 2007 Wiener Neustadt - Czelo
17/18 January 2007 Wiener Neustadt - Czelo
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Varna University of Medicine<br />
Address 55 Marin Drinov Street Bulgaria<br />
9002 - Varna<br />
Phone / Fax +359 52 65 00 61, ext.322 / +359 52 65 00 19<br />
www www.mu-varna.bg<br />
Size 250+<br />
Organisation Type University<br />
Contact Person<br />
Name Dr. Diana Ivanova<br />
Position International Coordinator FP7<br />
Email divanova@mu-varna.bg<br />
Type of co-operation (Offered, Requested) Areas of activity<br />
Licence agreement<br />
Technical Co-operation (R&D)<br />
Joint research project Requested<br />
Joint-venture agreement<br />
Manufacturing agreement<br />
Commercial agreement<br />
Financial agreement<br />
• Medicine, Human Health<br />
• Biology / Biotechnology<br />
• Food Technology<br />
•<br />
Short description of company<br />
We are part of the research community of Varna University of Medicine and our group involves members of the<br />
Department of Pharmacology, Chemistry and Biochemistry, Clinics of Hematology and the Department of<br />
Pathology. We are in collaboration with scientists fro Bulgarian Academy of Science and University “Babesh<br />
Bolyai” from Romania. Our research activities have been focused on toxicity testing using animal models o (1)<br />
silica and titanium dioxide nanopolymers and polybutylcyanoacrilate nanoparticles; (2) free and encapsulated in<br />
organic nanoparticles cytostatics. We are interested in scientific collaboration related to nanoparticle application<br />
as drug carriers.<br />
1. Profile: Reques Application of nanomaterials as drug delivery systems.<br />
DESCRIPTION: Polymer synthesis, characterization and toxicity testing on animal models; kinetics of drug<br />
release from the nanopolymers, comparative evaluation of toxicity of free and encapsulated in nanoparticles drug<br />
substances.<br />
INNOVATIVE ASPECTS: New systems for drug/substances delivery<br />
MAIN ADVANTADGES / BENEFITS: New systems for drug/substances delivery enabling controlled and specific<br />
drug release.<br />
TECHNICAL SPECIFICATIONS:<br />
CURRENT STAGE OF DEVELOPMEN Development Phase<br />
INTELLECTUAL PROPERTY RIGHTS (IPR):<br />
MARKET APPLICATIONS: Medicine, Pharmaceutical industry, Cosmetics<br />
TYPE OF COLLABORATION SOUGH Research/industry cooperation<br />
PARTNER PROFILE: Pharmaceutical/ Cosmetics company, Research institution interested in the application of<br />
nanomaterials for drug/substances delivery<br />
2. Profile: Reques Application of nanomaterials as drug delivery systems.<br />
3. Profile: Reques Application of nanomaterials as drug delivery systems.
Change language